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Editorial
do we need a new look in the definition of 
X-linked recessive disorders?
Precisamos ter uma nova visão da definição das desordens recessivas ligadas ao X?
Iscia Lopes-Cendes
The molecular revolution has changed permanently the practice of Medicine1. Nowadays, we are frequently faced with the challenge of identifying specific gene mutations when patients are seen, in order to confirm or to clarify a sus-pected diagnosis2. We have changed disease classification schemes to accom-
modate differences in their genetic bases3, and more recently we have developed therapeutic 
protocols based on differences in gene signature4. However, little has changed in the past de-
cades regarding the complex relationship between modern molecular genetics concepts and 
the definition of X-linked inheritance5. 
In fact, the concept of X-linked disorder we use today was proposed in the beginning of 
the 20th century and has changed very little6. The early concepts of dominance and recessive-
ness were first used for autosomal traits and, subsequently, they were somewhat adapted for 
the X-linked traits in order to define X-linked recessive and X-Linked dominant inheritance7. 
However, based on clinical experience with several X-linked disorders, it becomes clear that 
this concept needs revision5. 
The paper written by Lourenço et al.8 explores this issue in the context of an X-linked reces-
sive disorder, adrenoleukodystrophy, in which heterozygous females were previously believed 
to be clinically unaffected or to have a very mild phenotype9. This would be expected since 
in an X-linked recessive inheritance: males are predominantly affected; all their phenotypic 
healthy daughters are heterozygous; the mother of an affected male is heterozygous; among 
sons of heterozygous women, there is a 1:1 ratio between affected and unaffected; and one 
would only observe affected females if these were homozygous for the recessive allele10. 
The X and Y chromosomes, which are responsible for gender determination, are unevenly 
distributed between men and women. Therefore, the phenotypes determined by genes located 
on the X chromosome have a characteristic gender distribution and a peculiar pattern of in-
heritance. Men have only one X chromosome, while females have two, therefore there are two 
possible genotypes in men and three in women with respect to an allele in the X chromosome. 
A man with a mutant allele in a locus on the X chromosome is hemizygous for that allele, 
while a woman can be homozygous for the wild type allele, homozygous the mutant allele, or 
heterozygous (one wild type allele and one mutant allele)11. For that reason, to assure there is 
no gene dosage difference between men and women, a normal physiological process occurs, 
the X-chromosome inactivation, in which an X chromosome is inactivated in somatic cells of 
normal women, thereby equalizing the expression of most genes linked to the X chromosome 
in both sexes11. In normal female cells, the choice of which X chromosome will be inactivated 
is random, and it is maintained in each cell line derived, thereafter12. 
Females are mosaics for two-cell lines, one with the maternal X and one with the paternal X 
as the active chromosome12. The clinical relevance of X chromosome inactivation is profound, 
thus depending on the pattern of random inactivation of the X chromosomes, two females 
who are heterozygous for an X-linked disease may present very different clinical conditions, 
since they differ in the ratio of cells having the mutant allele on the active X chromosome. 
By definition, a “dominant” or “recessive” pattern of X-linked inheritance is distinguished 
based on the phenotype presented by the heterozygous females; therefore, it becomes evident 
the type of difficulties one may face when trying to study patterns of clinical presentation in 
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heterozygous female patients. Women who are heterozygous 
for the mutant allele may present, or not, the disease phe-
notype depending on the random pattern of X chromosome 
inactivation she carries12. This fact has prompted some au-
thors to recommend that the use of the terms X-linked re-
cessive and dominant be discontinued and simple replace by 
“X-linked” inheritance6. 
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At this point, the use of X chromosome inactivation tests 
is not current in clinical practice and may represent an ad-
ditional diagnostic problem, since there are many variables 
that need to be considered in such analysis13. Therefore, as 
very well stated by Lourenço et al.8, extra caution should be 
taken when evaluating female carries of X-linked recessive 
disorder. 
